Collects samples and health data from adults with immune-related inflammatory diseases
Collects samples and health data from adults with lupus, asthma, or other inflammatory conditions.
Plain-language title generated from the registry record
Registry title: Deployment o the Multidisciplinary Prospective Cohort Imminent
Key facts
- Where
- Lille, FranceSee the site
Where in France
- Hop Claude Huriez Chu LilleLille, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Lille
- Trial code
- NCT04334031
- Record updated
- 5 May 2026
- Original description
Immune-mediated inflammatory diseases (IMIDs) most often affect young patients and have high impact on morbidity and mortality with a significant alteration in the quality of life of patients with professional, social and emotional repercussions.Read full original descriptionShow less
Deployment o the Multidisciplinary Prospective Cohort Imminent
Immune-mediated inflammatory diseases (IMIDs) most often affect young patients and have high impact on morbidity and mortality with a significant alteration in the quality of life of patients with professional, social and emotional repercussions.
Beyond this burden, IMIDs share many common pathophysiological mechanisms and treatments, known as "targeted therapies". Despite progress in this field, much remains to be done in clinical, therapeutic and fundamental research to address the efficacy, resistance and side-effects of treatment.
These similarities between IMIDs have led the FHU IMMINeNT to propose the creation of a prospective, multidisciplinary clinical-biological database (IMMINeNT cohort), associated to a biobank, of patients with IMIDs. The main objectives of this database will be to identify new prognostic and therapeutic biomarkers in order to develop new therapeutic targets and biomarkers, to identify prognostic factors and determinants related to the activity, severity and quality of life of patients with IMIDs as well as to the response and tolerance to treatment.
Inclusion: Patient followed for their IMID in one of the departments of the Lille University Hospital participating in the study (dermatology, internal medicine, neurology, pneumology and rheumatology); Social insured; Have the capacity to understand the study requirements, provide written informed consent, and comply with the study data collection procedures.
Exclusion: Administrative reasons: inability to receive informed information, inability to participate in the entire study, lack of coverage by the social security system; Pregnant or breastfeeding woman; Persons deprived of liberty; Protected minors or adults; Persons who have refused or are incapable of giving informed consent; Persons in Emergency Situations.